i still think when you look at valuations, celgene at 15, gilead in the single digits. we all atalk about the cash. when will they do it they haven't done it yet. >> i can't say it's nothing. a relative green light has given the whole sector to run. celgene has run -- >> the absence of proposed regulation, not a regulatory -- >> i agree >>> coming up, president trump and india's prime minister modi are moments away from a joint press conference we'll bring you there live, tell you what the market implications could be. >>> also, did netflix just go from predator to prey? we'll talk to netflix co-founder mitch lowe and what facebook means for the streaming giant. >>> and martin chiarelli back in the spotlight. he heads back to court today and could put a bull's-eye on the back of biotech stocks we'll explain. much more "fast money" right after the break. welcome to holiday inn! ♪ ♪ whether for big meetings or little getaways, there are always smiles ahead at holiday inn. track your pack. set a curfew, or two. make dinner-time device free. [ music stops ] [ music plays ag

and there are plenty -- look, celgene is another name. >> celgene is a good name. biogen, you can be waiting for gilead to make an acquisition is like, it's taking forever. they should have done it let me make just a broader point, if i can. >> please. >> i just don't think, jimmy, and this is not criticizing you, that three years ago, without the market where it is and what we've seen in amazon and so many netflix, et cetera, that you would have ever, in your wildest dreams, considered alexion a value stock. >> no, three years, that was my point. >> three years ago >> zdespite the fact that stocks come down. >> nobody even now would consider it a value stock. >> exactly that there's been this creep -- >> i mean, you look at the valuation. >> what is the valuation >> it's in the high teens on an earnings multiple. you know, you've got to -- >> i'm looking -- that's on forward multiples, you're going out, or trailing multiples it's ridiculously expensive, right? >> it's not -- i wouldn't say it's ridiculously expensive. you've got to remember a couple of things. fir

it got unstuck for celgene. and biogen, 4. nice to see that. it's only one day. but nice to see the stock of wells fargo go up a dollar. the big national banks have been suffering from weakness from the trading division. however wells fargo supposed to be doing okay. perhaps that's how it could pop today. even the ceo, tim sloane said, loan growth is less robust than a year ago. and it does take 18 month chipotle-like for the american public to truly for give. wells fargo is the chipotle of banking. it's nice to see the stock can go up not just down. bottom line, the rap against this market, it was all fang all the time and some tesla. today, the market got broader, much broader and makes your more confident stocks can keep going higher even with the first five months of positive returns. gabriel from california. >> caller: jim, love your show. you're like the family member of my house hoeld. everybody knows at 3:00 i have my hot tea and jim cramer. >> what's up? >> i wanted to know if you think exxonmobil is safe or change my position in exxonmobil? >> we won't

lastly, when we look at celgene, it's a good chart. you have this big trading range coming out of in relative performance is starting to hook up, so i think the call here is as we move to the summer months, there's risk in the market people are trying to get more defensive. growth managers don't have a lot of places to go, so i think they can start looking at health care >> so, obert, going back to th very first chart you address aed, which was the chart of technology, are you seeing a breakdown in technology or jaus stal just a stahl zpl i think it's a stahl we had the chop, the big move last friday where all the volatility ip creased. a few names moved down 10, 15% just to the 200 day moving average on the s&p 500 technology sector is another 10% drop and probably 20%. i think it will move into the summer and fall. >> robert, thank you so, karen, take a look at the chart like that. you hold a lot of those big cap technology kind of stocks. is there a concern as we see the strength in health care. >> if you're a large cap growth fund,

. >> that came out of celgene. >> an amazing cancer company.at out to focus on stem cells for regenerative medicine. another are using stem cells to regrow part of the lungs and kidneys. in the future, if you have a heart attack or a lungs or liver, you will regrow a set of organ, i'm talking about you are not this year, in 20 years, that's decades, these technologies are coming online. >> an amazing person knife therapeutics. >> reporter: people get excited within they har you talk. one of the problems is they say how do we invest alongside with you in the future, some of this of course is not publicly traded. is there a way to do that? >> i started a bold partner capitals, we are investing in exponential technology that impacts billions of problems. a lot of opportunities, if people are interested dianandis.com. i talk about where i am investing my capitals and where they are. >> reporter: you are an investor, what are you putting your money in right now publicly traded? >> it's interesting, there are a few giants that will remain giants, goo

. >> i like cell celgene is. >> does not any friday, it's national donut day.rco is asking which favorite? >> you always go with the glazed. >> glazed, krispy kreme. >> powder jelly. >> wow. that's a mess right there. >> a surprise. >> a big mess. >> all right, it's time now for the final call. >> that is the last word from the options pit. carter, you are up first. >> amgen. >> do not be tempted for hot dividends in oil stocks. >> yes, soon apple, if you have fantastic gains, it's selling the money call, buying the money put, protecting your gains to offerings. >> you guys have a great weekend. it's been a pleasure being with all of you. it looks like our time has expi. we'll be back next. >> there's always work somewhere, i promise to help you find it. "mad money" starts now. >>> hey, i'm, kraim, welcome to "mad money." my job is not just to entertain but to educate and teach you. okay, so ware not creating as many jobs louis lot of people thought.

issues, a lot of margin issues i would go with gilead, to me, of all the name, i know we talk about celgene, to be long! this isy valuation is stupid cheap. i know it has been for a long time, but at some point, it begcomes a relative point and fr a sector where not only is the regulatory target coming off, but this is a company whose core businesses are doing fine. >> what's been extraordinary is that it's been made on heavy volume for days in a row wasn't just one day of heavy volume >> then you add in everything else that we've seen with the health care sector when you talk about the drug companies, the insurance companies, everything is adding up to this bio tech, i still long that because i still think there's a wave of m&a coming if you can clear waway some of the uncertainty that big pharma has to buy, to me, i like that i also like a and d. i think there's multiple reasons to buy that. one is because of the mining phase. that's going on. but there are other reasons to buy amd, which we've seen in run up and we haven't seen the 2017, february 2017 highs. so i think there's more to go

. >> i like celgene. it looks like a value play here.not just any friday, it's national doughnut day. that has marco asking which doughnuts are the favorites? >> going for brand or flavor? >> flavor. >> glazed. you always go with the glazed. >> glazed, krispy kreme. >> powdered jelly. >> what? >> powdered jelly. that's a mess. >> not surprised. >> not sure about the jelly. time for the final call. that's the last word from the options pitch. carter? amgen. >> do not be tempted by the high dividends in oil stocks. >> apple, fantastic gains. the opportunity of buying out of the money put, protecting gains do to the down side. >> you have a great weekend. it looks like our time has expired, sad clown face. we'll be back next friday for more options action. >> the following is a paid presentation, brought to you by beachbody, but filmed by me on my iphone and directly from my heart. >> hold up. i want to ask you a question. how do you feel when you look at yourself in the mirror? not so good. like, "ugh. gross." who is this person? like, you

starting earlier with celgene and roche. other big stocks to watch on monday. sara?portant conversations. thank you for studying it up, meg tirrell at headquarters. >>> let's send it out to sue herera with an update. sue? >> thank you, sara. trump administration asking the supreme court to reinstate its ban on travelers from six predominantly muslim countries. the administration says the nation would be safer if that policy is put in place. >>> four people were killed as hundreds of protesters took to the streets of kabul in the wake of wednesday's extremist attack that killed at least 90 people and injured more than 450 others. protests turned violent when the demonstrators tried to get closer to the presidential palace. >>> 36 people died in addition to the gunman during an attack on a casino in manila. most died of suffocation as the gunman set gaming tables on fire. he fleed with $2 million in gaming chips before setting himself on fire. >>> and prince william meets at the headquarters with the greater manchester police. the bombi ining last week kille people. sa

however the partner was celgene and the stock hasn't done much as of late so maybe that's a lower risklay and of course a lower reward play in order to get into the stock. the third biggest winner, interesting. it's another company focused on breast cancer. it's intriguing because it's already round tripped. stock rocketed from $81 to $92 on monday but it closed up 2% and since then approximate pulled back further to $79 although most of the profit taking has to do with the fact that puma already doubled going from $31 on may 15th to $76 on may 31st after an fda panel recommended it for approval. the company also presented positive data from its on going phase 2 trial from the treatment of what's known as her 2 positive breast cancer that's ea t metasti metastisized to the brain. the fact that they had a response rate with median patient survival coming in was good. my view of the situation they need to digest the earlier rally. if you want to speculate on this one i consider letting it continue to unfold before you pull the trigger. what about the possible losers at this conference. t

thanks to a positive ruling in its patent battle against amgen and the launch of a new eczema drug celgeneprts % in te second half. the worst performers, vertex falls 9%, labcorps dips 2% >> the whole sector will watch and see what becomes of that senate bill. landon, thank you. >>> now for some top trending stories. the "washington post" reporting that a fake "time" magazine cover bearing trump's image is hanging in five trump golf clubs. time has asked they be removed they read donald trump's apprentice is a splash a time spokesperson says the real time cover that week featured kate winslet. >>> cadburys has been hit by a massive cyberattack. computers at the factory stopped working last nights forring it to shut down production. it's unclear when production may resume i think there may be global capacity for chocolate production >> to make up for this never know it is broad. >> the attack is >>> britney spears' is slamming decades of lip-sync accusations. in an interview with an israeli tv show, the pop superstar admits she uses a bit of playback, but also uses her own voice in performa

celgene in sector up 13%. that sector did well. under pressure. at&t, verizon coming under pressure. last but not least tech. everybody loves tech. they have it in their 401(k)s the idea it will do well throughout the year. you have to hold on for that group. it is up 63 and higher for the quarter, first half of the year. melissa: nicole, thank you so much. phil, oil crushed so far this year. wow, look at that chart. >> it looked ugly in the beginning of the year. what a turnaround last couple days. i think when summer hit the world, the market turned around. we're seeing market turn around. we have been up seven days in a row on the price of oil, melissa. first time since opec production cuts went into effect, we saw u.s. rig counts fall. that set stage for big rally. shale kind of topped out here, are investor pulling back. maybe a big drop on the chart is reason we saw rig counts start to fall today. melissa: maybe. good to know he, phil. i like that perspective. thank you. david? david: distraction from the economy. investor waiting on health

we sat down with the ceo of celgene and pricing was the big topics that comes up at the conference.aid. >> we would never ask a patient who has to go into the hospital for surgery to pay up to 50% out of pocket for the surgical procedure. yet, the insurance schemes and many of the things we do for cancer patients we force them to have high deductibles and high coinsurance on the medicines that are the only option for them to live longer and better lives. i see a lot of collaboration, enough of the blame game. let's come together on access and affordability. >> so the celgene ceo talked about a lot of government focus on the drug pricing right now. and they have some updates in multiple mile loma, guys. back to you. >> thank you. >>> the man behind oculus pr blotting a -- plotting a comeback. palmer luckey sold his stock when he was 20 years old and he's got a new start-up in the works and it's a virtual border wall. paging president donald trump. they're developing surveillance technology that could be deployed around the military bases. we need to create superior technology to keep

fooled it didn't go back into oil low tech health care, also higher valuation health care you watch celgenend biotech. watch illinois tool works which is a great tell for the industrial you can watch jpmorgan, you can watch the trading of wells fargo. there was a real rotation going on there was not a lot of money driving it everyone wants to attribute this to things that were said by yellen this is exactly what was going on on friday somebody wants out of these kind of stocks. we can be in the market right now where it could be somebody -- maybe a large mutual fund there's nothing going on in the companies. now today analysts who are -- who had been on the fence come out and now we have a downgrade of spelunk for competition and we got a downgrade of nvidia, competition. an interesting downgrade from canaccord about alphabet there's nothing. it doesn't matter. these are the days you do that very interesting because yesterday goldman had to bump up nvidia nvidia is the ultimate battleground because it's doing very well. but tim cook, might want to jump up and down on artificial intelligence